Welcome to our dedicated page for Biohaven Ltd. news (Ticker: BHVN), a resource for investors and traders seeking the latest updates and insights on Biohaven Ltd. stock.
Biohaven Ltd. (NYSE: BHVN) is a leading clinical-stage biopharmaceutical company dedicated to the discovery, development, and commercialization of transformative treatments in key therapeutic areas, including immunology, neuroscience, and oncology. Leveraging multiple proprietary drug development platforms, Biohaven is advancing an impressive product pipeline that addresses a variety of diseases, ranging from neuromuscular and metabolic disorders to antibody-drug conjugates for cancer and obsessive-compulsive disorder.
Biohaven's notable product candidates include:
- Glutamate Modulation: Troriluzole, currently in Phase 3 trials for obsessive-compulsive disorder, offers hope for patients with inadequate responses to standard treatments.
- Myostatin Inhibition: Taldefgrobep alfa, in Phase 3 studies for spinal muscular atrophy and being evaluated for obesity treatment, targets muscle growth regulation pathways.
- Ion Channels: BHV-7000, a selective activator of Kv7.2/7.3 potassium channels, is in clinical development for epilepsy and mood disorders.
- Inflammation & Immunology: BHV-1300 and BHV-1310, from the innovative extracellular protein degradation platform, aim to treat autoimmune diseases by lowering IgG levels.
- Oncology: BHV-1510, a Trophoblast Cell Surface Antigen-2 (Trop-2) directed ADC, shows promise in treating select advanced epithelial tumors.
Recent milestones highlighted at the 42nd Annual J.P. Morgan Healthcare Conference and other events include significant progress in these areas and the initiation of pivotal human studies. CEO Dr. Vlad Coric emphasized the company's strong focus on neuroscience, immunology, and oncology, with near-term potential in these fields.
Financial updates reveal solid funding for future advancements, supported by a public offering that raised $230 million. Biohaven's robust clinical and preclinical pipelines are backed by an experienced leadership team and a strong financial foundation, underlining the company's capacity for rapid, efficient drug development.
The company’s leadership in neuroscience was underscored at the 2024 American Academy of Neurology Annual Meeting, featuring multiple presentations on Kv7 ion channel modulation, MoDEs, TRPM3 antagonism, and TYK2/JAK1 inhibition. Looking ahead, Biohaven is poised for a groundbreaking year, with multiple INDs planned and significant clinical data expected across its portfolio.
For more information, visit Biohaven's website.
Biohaven Pharmaceutical (NYSE: BHVN) reported a strong Q4 2020, with net product revenues from NURTEC ODT reaching $35.1 million, a 98% increase from Q3. Full-year revenues totaled $63.6 million following the product's FDA approval in February 2020. Despite pandemic challenges, NURTEC ODT's market growth reflects unmet patient needs in migraine treatment. The company also submitted an EU marketing application for rimegepant for acute and preventive migraine treatment. Full-year net loss was $766.8 million, with R&D expenses of $229 million, while SG&A expenses surged to $462.3 million.
Biohaven Pharmaceutical Holding Company Ltd. (NYSE: BHVN) will host a conference call on March 1, 2021, at 8:30 a.m. ET to discuss its fourth quarter and full year 2020 financial results and recent business developments. Investors can access the call via phone or through the company’s website. Biohaven specializes in innovative therapies for neurological and neuropsychiatric conditions, with an FDA-approved product, NURTEC® (rimegepant), and a promising pipeline targeting migraine, OCD, and more.
Biohaven Pharmaceutical Holding Company (NYSE: BHVN) announced promising results for BHV-1200, a hyperimmune globulin mimic developed using its MATE platform, demonstrating its ability to neutralize SARS-CoV-2 and variants B.1.1.7 and B.1.351. Preliminary tests showed significant reduction in viral entry into cells. The development of this COVID-19 treatment has garnered support from the Bill and Melinda Gates Foundation. The CEO expressed excitement about advancing BHV-1200 into clinical trials, highlighting its potential advantages over existing therapies.
Biohaven Pharmaceutical holds announced preliminary net product revenue of $35 million for NURTEC ODT in Q4 2020, a staggering 98% increase compared to Q3. Total prescriptions for 2020 exceeded 337,000 with over 24,000 unique prescribers. The revenue projection is preliminary and based on unaudited data. CEO Vlad Coric highlighted strong market momentum despite pandemic challenges, noting positive feedback from patients and physicians. NURTEC ODT, a CGRP receptor antagonist, was FDA-approved for migraine treatment in February 2020 and launched in March.
Biohaven Pharmaceuticals (NYSE:BHVN) has signed Cody Ware to pilot the Nurtec® ODT #51 Chevrolet Camaro for the 2021 NASCAR Cup Series season. The partnership kicks off at the DAYTONA 500 on February 14. Ware, who has personal experience with migraines, aims to raise awareness about the condition and Nurtec ODT, the first and only FDA-approved CGRP receptor antagonist in an orally disintegrating tablet form for acute migraine treatment. Biohaven's CEO expressed excitement about this collaboration, highlighting the importance of effective migraine treatments.
Biohaven Pharmaceutical (BHVN) announced the results of its Phase 2/3 trial of troriluzole for treating mild-to-moderate Alzheimer's disease. The drug did not show a statistically significant difference from placebo on co-primary endpoints at 48 weeks. However, a subgroup analysis indicated a non-significant numerical benefit in mild AD patients. Full results, including additional biomarker analyses, will be available soon. The treatment was well-tolerated, prompting plans for an amendment to the ongoing long-term study to gather more data.
Biohaven Pharmaceutical (NYSE: BHVN) announced its acquisition of the remaining 58% stake in Kleo Pharmaceuticals, enhancing its portfolio with innovative bispecific compounds for immunotherapy. The acquisition, valued at approximately $20 million, allows Biohaven to integrate Kleo's chemistry capabilities at the newly established Biohaven Labs in New Haven, Connecticut. Additionally, Biohaven secured an exclusive license from Yale University for a novel extracellular degrader technology. This strategic move positions Biohaven to expand its product development in oncology and autoimmune disorders.
Biohaven Pharmaceuticals (NYSE:BHVN) announced that its migraine treatment, Nurtec ODT, will sponsor the #51 Ligier JS P217 at the 2021 24 Hours of Daytona race. This event, taking place at Daytona International Speedway on January 30-31, marks a significant partnership with Eurasia Motorsports and BAM Motorsports Management. Drivers Austin Dillon and Cody Ware will pilot the car. CEO Vlad Coric emphasized the importance of raising awareness for migraine disease through this initiative. Nurtec ODT, the first orally disintegrating tablet for migraine relief, received FDA approval in February 2020.
Biohaven Pharmaceutical Holding Company (BHVN) has begun enrollment for a Phase 3 clinical trial to examine the safety and efficacy of troriluzole in patients with obsessive-compulsive disorder (OCD). The trial involves a 280 mg once-daily dose and aims to enroll approximately 600 patients across both the U.S. and Europe. Previous Phase 2 studies indicated a clinically meaningful effect, despite lacking statistical significance. This trial is crucial as no new OCD treatments have been approved in over two decades, and approximately one-third of OCD patients do not respond to current therapies.
FAQ
What is the current stock price of Biohaven Ltd. (BHVN)?
What is the market cap of Biohaven Ltd. (BHVN)?
What does Biohaven Ltd. specialize in?
What are some of Biohaven's key product candidates?
What recent milestones has Biohaven achieved?
How is Biohaven funded for its future projects?
What is Biohaven's approach to treating autoimmune diseases?
Where can I find more information about Biohaven's clinical trials?
Who leads Biohaven Ltd.?
What are the primary therapeutic areas Biohaven is focusing on in 2024?
What recent events highlight Biohaven's advancements in neuroscience?
How does Biohaven plan to use the funds from its recent offering?
